Table 3.

Comparison of treatment planning dosimetry goals for the target volume: CTV and PTV and OARs planning constraints used for the SBRT-SIB plans according to prescribed dose to the DILs (40Gy, 45Gy, 47.5Gy, and 50Gy).

Structure	Parameter	SBRT-SIB plan (mean+SD) // evalution by the DIL the prescibed dose					Overall	Multiple comparsions
								40vs.45	40vs.47.5	40vs.50	45vs.47.5	45vs.50	47.5vs.50
		SIB_40Gy	SIB_45Gy	SIB_47.5Gy	SIB_50Gy		p-value	p-value < 0.05
CTV(boost)	V95%	99.71 ± 0.58	100.00 ± 0.00	99.96 ± 0.14	99.87 ± 0.51		0.185	0.059	0.105	0.428	0.326	0.326	0.49
PTV(boost)	V95%	95.31 ± 0.64	95.07 ± 0.26	95.07 ± 0.26	95.15 ± 0.44		0.391	0.195	0.189	0.453	0.972	0.536	0.52
CTV(Prostate)	V98%	98.70 ± 1.25	99.04 ± 1.88	99.26 ± 1.15	98.89 ± 1.60		0.766	0.565	0.206	0.711	0.692	0.824	0.472
PTV(Prostate)	V95%	96.55 ± 1.33	96.60 ± 1.49	96.98 ± 0.87	97.60 ± 0.91		0.068	0.921	0.3	0.018	0.399	0.036	0.7
	Dmax	104.05 ± 0.87	105.49 ± 0.88	106.38 ± 1.11	106.91 ± 0.92		<0.001	<0.001	<0.001	<0.001	0.023	<0.001	0.163
	CI	1.15 ± 0.04	1.15 ± 0.04	1.15 ± 0.03	1.18 ± 0.03		0.092	0.669	0.823	0.055	0.787	0.031	0.013
	HI	1.14 ± 0.01	1.29 ± 0.02	1.37 ± 0.02	1.44 ± 0.03		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
	GI	3.18 ± 0.06	3.19 ± 0.04	3.20 ± 0.04	3.21 ± 0.05		0.355	0.6	0.343	0.124	0.642	0.234	0.397
PTV(Prostate) – PTV(boost)	V95%	96.40 ± 1.39	96.46 ± 1.55	96.86 ± 0.88	97.49 ± 0.95		0.069	0.907	0.288	0.018	0.396	0.038	0.07
Rectum	V 36Gy < 1cc	0.37 ± 0.12	0.36 ± 0.13	0.38 ± 0.06	0.42 ± 0.11		0.494	0.81	0.835	0.28	0.613	0.192	0.231
	V 36.25Gy < 5%	0.89 ± 0.29	0.89 ± 0.33	0.95 ± 0.16	1.03 ± 0.29		0.487	0.988	0.527	0.211	0.551	0.234	0.36
	V 32.60Gy < 10%	2.87 ± 0.69	2.61 ± 0.54	2.61 ± 0.31	3.02 ± 0.51		0.099	0.262	0.195	0.502	0.997	0.042	0.013
	V 29Gy < 20%	5.91 ± 0.83	5.50 ± 0.61	5.58 ± 0.59	6.27 ± 0.82		0.019	0.138	0.219	0.234	0.727	0.001	0.012
	V 18Gy < 50%	23.66 ± 1.64	22.98 ± 0.97	23.61 ± 2.56	26.09 ± 3.48		0.004	0.861	0.999	0.033	0.888	0.004	0.029
Bladder	V 37Gy < 10cc	4.11 ± 0.76	4.27 ± 0.57	4.42 ± 0.29	4.65 ± 0.30		0.041	0.516	0.155	0.016	0.39	0.031	0.038
	V 36.25Gy < 10%	3.78 ± 0.40	3.76 ± 0.42	3.84 ± 0.24	4.02 ± 0.24		0.141	0.935	0.57	0.051	0.542	0.048	0.048
	V 32.60Gy < 15%	5.66 ± 0.35	5.54 ± 0.40	5.58 ± 0.30	5.78 ± 0.29		0.235	0.398	0.542	0.302	0.302	0.069	0.077
	V 29Gy < 25%	7.21 ± 0.38	7.06 ± 0.42	7.10 ± 0.35	7.32 ± 0.33		0.217	0.315	0.403	0.393	0.795	0.068	0.08
	V 18Gy < 55%	12.63 ± 0.48	12.44 ± 0.53	12.48 ± 0.47	12.80 ± 0.46		0.185	0.311	0.4	0.342	0.82	0.058	0.074
Femoral head R	V 18Gy < 4 cc	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00		0.267	<0.001	0.326	0.162	0.326	0.162	0.483
Femoral head L	V 18Gy < 4 cc	0.00 ± 0.00	0.00 ± 0.00	0.01 ± 0.04	0.00 ± 0.02		0.85	0.326	0.326	0.302	0.346	0.346	0.649
Skin	Dmax < 15Gy	10.98 ± 0.61	10.91 ± 0.39	11.35 ± 0.90	11.58 ± 0.81		0.037	0.705	0.195	0.03	0.091	0.007	0.473
Monitor units	MU	2277 (1986-2538)	2280 (2042-2574)	2372 (2100-2879)	2426 (2070-3149)		0.091	0.952	0.15	0.049	0.166	0.055	0.501

The bold numbers indicate significant differences between the plans (ANOVA test).